Order Article Reprints

Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, et al. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers. 2019; 11(9):1271. https://doi.org/10.3390/cancers11091271

Heeke, Simon, Jonathan Benzaquen, Elodie Long-Mira, Benoit Audelan, Virginie Lespinet, Olivier Bordone, Salomé Lalvée, Katia Zahaf, Michel Poudenx, Olivier Humbert, and et al. 2019. "In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients" Cancers 11, no. 9: 1271. https://doi.org/10.3390/cancers11091271

Heeke, S., Benzaquen, J., Long-Mira, E., Audelan, B., Lespinet, V., Bordone, O., Lalvée, S., Zahaf, K., Poudenx, M., Humbert, O., Montaudié, H., Dugourd, P.-M., Chassang, M., Passeron, T., Delingette, H., Marquette, C.-H., Hofman, V., Stenzinger, A., Ilié, M., & Hofman, P. (2019). In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 11(9), 1271. https://doi.org/10.3390/cancers11091271